FDA cautions device users on fracture risk
This article was originally published in The Gray Sheet
Executive Summary
FDA warns health care practitioners Jan. 15 of risks associated with device fragments breaking off inside patients and not being retrieved. The agency's device center receives nearly 1,000 reports a year of adverse events including infection, tissue perforation, blood vessel obstruction and death resulting from unretrieved fragments, according to the public health 1notification, which advises physicians on prevention and how to respond if needed. According to an agency spokeswoman, fracture risk is a problem for devices across-the-board, but the highest incidence of reports relates to coronary catheter guidewires, implanted intravascular ports with catheters and bone screws. "This may reflect the high volume of usage of these devices rather than an actual high rate of fracture," she said. "In addition, the difficulty in removing fragments of these devices may contribute to their being unretrieved.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.